IMAGEN Proposal

1 Department of Child and Adolescent Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Square J5, 68159 Mannheim, Germany;

2 Department of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, United Kingdom;

3 Discipline of Psychiatry, School of Medicine and Trinity College Institute of Neuroscience, Trinity College Dublin, Dublin, Ireland;

4 Physikalisch-Technische Bundesanstalt (PTB), Braunschweig and Berlin, Germany;

5 Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, United Kingdom;

6 Institute of Cognitive and Clinical Neuroscience, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Square J5, Mannheim, Germany;

7 Department of Psychology, School of Social Sciences, University of Mannheim, 68131 Mannheim, Germany;

8 Departments of Psychiatry and Psychology, University of Vermont, 05405 Burlington, Vermont, USA;

9 Sir Peter Mansfield Imaging Centre School of Physics and Astronomy, University of Nottingham, University Park, Nottingham, United Kingdom;

10 NeuroSpin, CEA, Université Paris-Saclay, F-91191 Gif-sur-Yvette, France;

11 Department of Psychiatry and Psychotherapy CCM, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany;

12 Institut des Maladies Neurodégénératives, UMR 5293, CNRS, CEA, Université de Bordeaux, 33076 Bordeaux, France;

13 Institut National de la Santé et de la Recherce Médicale, INSERM U A10 "Trajectoires développementales & psychiatrie", University Paris-Saclay, Ecole Normale Supérieure Paris-Saclay, CNRS; Centre Borelli, Gif-sur-Yvette, France;

14 AP-HP. Sorbonne Université, Department of Child and Adolescent Psychiatry, Pitié-Salpêtrière Hospital, Paris, France;

15 Psychiatry Department, EPS Barthélémy Durand, Etampes, France;

16 Institute of Medical Psychology and Medical Sociology, University Medical Center Schleswig Holstein, Kiel University, Kiel, Germany;

17 Department of Psychiatry, Faculty of Medicine and Centre Hospitalier Universitaire Sainte-Justine, University of Montreal, Montreal, Quebec, Canada;

18 Departments of Psychiatry and Psychology, University of Toronto, Toronto, Ontario, Canada;

19 Department of Child and Adolescent Psychiatry, Center for Psychosocial Medicine, University Hospital Heidelberg, Heidelberg, Germany;

20 Department of Psychiatry and Psychotherapy, Technische Universität Dresden, Dresden, Germany;

21 Centre for Population Neuroscience and Stratified Medicine (PONS), Department of Psychiatry and Psychotherapy, Charité Universitätsmedizin Berlin, Germany;

22 School of Psychology and Global Brain Health Institute, Trinity College Dublin, Ireland;

23 Centre for Population Neuroscience and Precision Medicine (PONS), Institute for Science and Technology of Brain-inspired Intelligence (ISTBI), Fudan University, Shanghai, China.

Dr Banaschewski served in an advisory or consultancy role for Lundbeck, Medice, Neurim Pharmaceuticals, Oberberg GmbH, Shire. He received conference support or speaker’s fee by Lilly, Medice, Novartis and Shire. He has been involved in clinical trials conducted by Shire & Viforpharma. He received royalties from Hogrefe, Kohlhammer, CIP Medien, Oxford University Press. The present work is unrelated to the above grants and relationships. Dr Barker has received honoraria from General Electric Healthcare for teaching on scanner programming courses. Dr Poustka served in an advisory or consultancy role for Roche and Viforpharm and  received speaker’s fee by Shire. She received royalties from Hogrefe, Kohlhammer and Schattauer. The present work is unrelated to the above grants and relationships. The other authors report no biomedical financial interests or potential conflicts of interest.

This work received support from the following sources: the European Union-funded FP6 Integrated Project IMAGEN (Reinforcement-related behaviour in normal brain function and psychopathology) (LSHM-CT- 2007-037286), the Horizon 2020 funded ERC Advanced Grant ‘STRATIFY’ (Brain network based stratification of reinforcement-related disorders) (695313), Horizon Europe ‘environMENTAL’, grant no: 101057429, UK Research and Innovation (UKRI) Horizon Europe funding guarantee (10041392 and 10038599), Human Brain Project (HBP SGA 2, 785907, and HBP SGA 3, 945539), the Chinese government via the Ministry of Science and Technology (MOST). The German Center for Mental Health (DZPG), the Bundesministerium für Bildung und Forschung (BMBF grants 01GS08152; 01EV0711; Forschungsnetz AERIAL 01EE1406A, 01EE1406B; Forschungsnetz IMAC-Mind 01GL1745B), the Deutsche Forschungsgemeinschaft (DFG grants SM 80/7-2, SFB 940, TRR 265, NE 1383/14-1, 186318919 [FOR 1617], 178833530 [SFB 940], 386691645 [NE 1383/14-1], 402170461 [TRR 265], 454245598 [IRTG 2773]), the Medical Research Foundation and Medical Research Council (grants MR/R00465X/1 and MR/S020306/1), the National Institutes of Health (NIH) funded ENIGMA-grants 5U54EB020403-05, 1R56AG058854-01 and U54 EB020403 as well as NIH R01DA049238, the National Institutes of Health, Science Foundation Ireland (16/ERCD/3797). NSFC grant 82150710554. Further support was provided by grants from: - the ANR (ANR-12-SAMA-0004, AAPG2019 - GeBra), the Eranet Neuron (AF12-NEUR0008-01 - WM2NA; and ANR-18-NEUR00002-01 - ADORe), the Fondation de France (00081242), the Fondation pour la Recherche Médicale (DPA20140629802), the Mission Interministérielle de Lutte-contre-les-Drogues-et-les-Conduites-Addictives (MILDECA), the Assistance-Publique-Hôpitaux-de-Paris and INSERM (interface grant), Paris Sud University IDEX 2012, the Fondation de l’Avenir (grant AP-RM-17-013 ), the Fédération pour la Recherche sur le Cerveau;

NB: Any paper to do with substance use requires this additional acknowledgement…

ImagenPathways "Understanding the Interplay between Cultural, Biological and Subjective Factors in Drug Use Pathways" is a collaborative project supported by the European Research Area Network on Illicit Drugs (ERANID). This paper is based on independent research commissioned and funded in England by the National Institute for Health Research (NIHR) Policy Research Programme (project ref. PR-ST-0416-10001), [...list other involved countries / national funding agencies]. The views expressed in this article are those of the authors and not necessarily those of the national funding agencies or ERANID.

NB: Any paper to do with substance use requires this additional acknowledgement… 

ImagenPathways "Understanding the Interplay between Cultural, Biological and Subjective Factors in Drug Use Pathways" is a collaborative project supported by the European Research Area Network on Illicit Drugs (ERANID). This  paper is based on independent research commissioned and funded in England by the National Institute for Health Research (NIHR) Policy Research Programme (project ref. PR-ST-0416-10001), [...list other involved countries / national funding agencies]. The views expressed in this article are those of the authors and not necessarily those of the national funding agencies or ERANID.